Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients

Obradovic, Jasmina; Jurišić, Vladimir

doi:10.1186/2049-6958-7-52

Cited by 10 publications

(6 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several standard methods exist to measure expression changes in PM proteins, including immunocytochemistry (Obradovic and Jurisic, 2012) and techniques utilizing other proteinspecific probes (Liu et al, 2005). Changes in the expression of PM proteins can also be detected with transductionally targeted recombinant viruses, which are able to enter only those cells with the appropriate ligand exposed on the PM.…”

Section: Plasma Membrane-associated Proteinsmentioning

confidence: 99%

Biomarkers to identify and isolate senescent cells

Matjusaitis

Chin

Sarnoski

et al. 2016

Ageing Research Reviews

124

108

View full text Add to dashboard Cite

Highlights There is no single biomarker which can robustly identify senescent cells. Widely used senescent cell biomarkers should be used in combination for accuracy. Technologies like tangential flow filtration can be used to isolate senescent cells. Other methods, like senolytic viruses, could be used to remove senescent cells. AbstractAging is the main risk factor for many degenerative diseases and declining health. Senescent To better understand cell aging and to reap the benefits of senescent cell removal, it is necessary to have a reliable biomarker to identify these cells. Following an introduction to cellular senescence, we discuss several classes of biomarkers in the context of their utility in identifying and/or removing senescent cells from tissues. Although senescence can be induced by a variety of stimuli, senescent cells share some characteristics that enable their identification both in vitro and in vivo. Nevertheless, it may prove difficult to identify a single biomarker capable of distinguishing senescence in all cell types. Therefore, this will not be a comprehensive review of all senescence biomarkers but rather an outlook on technologies and markers that are most suitable to identify and isolate senescent cells.

show abstract

Section: Plasma Membrane-associated Proteinsmentioning

confidence: 99%

Biomarkers to identify and isolate senescent cells

Matjusaitis

Chin

Sarnoski

et al. 2016

Ageing Research Reviews

124

108

View full text Add to dashboard Cite

show abstract

“…In this regard, many methods were developed to detect commonly known mutations and to screen new mutations of the EGFR in CRC but mainly in non-small cell lung cancer [28]. Epidermal growth factor EGF is frequently found co-expressed with EGFR in various types of cancer including colorectal adenocarcinoma [29].…”

Section: Product Of Pcr-rflp Analysis Of Egf A61g (Left) and P53 Arg7mentioning

confidence: 99%

“…These networks activate or deactivate some transcription factors regulating some proteins responsible for the death or survival of cell. Expression of both EGF and EGFR have been described to be significantly increased in a various human tumours including breast [26], lung [27][28] and colorectal adenocarcinoma [29].…”

Section: Introductionmentioning

confidence: 99%

Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population

et al. 2014

View full text Add to dashboard Cite

AbstractDuring the transformation process single nucleotide polymorphisms (SNPs) of key genes, such as p53 Arg72Pro or EGF A61G, may mediate various cellular processes. These variants may be associated with colorectal cancer risk (CRC), but conflicting findings have been reported. The purpose of this study was to determine the association of the SNPs in 5′ UTR of EGF A61G and p53 Arg72Pro and CRC in the Slovak population. The present case-control study was carried out in 173 confirmed CRC patients and 303 healthy subjects. Genotyping was performed by PCR-RFLP methods. Significant association was observed between age and CRC risk (p=0.001). Lower CRC risk was seen in younger patients carrying genotype p53 Arg72Pro (0.14; 95% CI 0.02–0.99, p=0.049). Gender-stratified analysis showed a significant inverse association of the polymorphism EGF G61G with CRC risk (0.48; 95% CI 0.2–0.9, p=0.04) only in male patients. Tumour site genotype distribution revealed that female patients with localized colon cancer were significantly associated with p53 Pro72Pro genotype (4.0; 95% CI 1.27–12.7, p=0.04) whereas the cancer of rectosigmoid junction was associated with the EGF G61G genotype (4.5; 95% CI 1.2–16.97, p=0.02). Combination of p53 Arg72Pro or EGF A61G polymorphisms were not associated with CRC risk by using logistic regression.

show abstract

“…PNA clamp primers competitively inhibit mutant LNA probes to bind to the wild type, further increasing the specificity of detection. In this way, EGFR mutations can be detected in the presence of 100- to 1,000-fold wild-type EGFR background [ 38 , 39 ]. Because of its high sensitivity and specificity, PNA-LNA PCR clamp was considered suitable to detect EGFR mutations in histological samples such as surgical specimens as well as in cytological samples such as sputum and pleural effusions [ 40 – 43 ].…”

Section: Assays For Egfr Mutations Using Ctdna In Plasma Samplesmentioning

confidence: 99%

“…In EGFR mutation analysis, mutations in exons 18 to 21 were analyzed using a DNA endonuclease, SURVEYOR assay, which cleaved mismatched heteroduplexed DNA [ 55 ]. For these analyses DNA could be prepared from both frozen and formalin-fixed, paraffin-embedded (FFPE) tumor specimens as well as ctDNA from plasma [ 38 , 56 , 57 ]. Furthermore, a partially denaturing HPLC (pDHPLC) assay was developed to detect a large range of sequence variants with high sensitivity and low detection limits for minority alleles which could be a useful approach for routine detection of EGFR variants [ 58 ].…”

Section: Assays For Egfr Mutations Using Ctdna In Plasma Samplesmentioning

confidence: 99%

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer

Huang

Fang

Wong

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

The advances in targeted therapies for lung cancer are based on the evaluation of specific gene mutations especially the epidermal growth factor receptor (EGFR). The assays largely depend on the acquisition of tumor tissue via biopsy before the initiation of therapy or after the onset of acquired resistance. However, the limitations of tissue biopsy including tumor heterogeneity and insufficient tissues for molecular testing are impotent clinical obstacles for mutation analysis and lung cancer treatment. Due to the invasive procedure of tissue biopsy and the progressive development of drug-resistant EGFR mutations, the effective initial detection and continuous monitoring of EGFR mutations are still unmet requirements. Circulating tumor DNA (ctDNA) detection is a promising biomarker for noninvasive assessment of cancer burden. Recent advancement of sensitive techniques in detecting EGFR mutations using ctDNA enables a broad range of clinical applications, including early detection of disease, prediction of treatment responses, and disease progression. This review not only introduces the biology and clinical implementations of ctDNA but also includes the updating information of recent advancement of techniques for detecting EGFR mutation using ctDNA in lung cancer.

show abstract

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients

Cited by 10 publications

References 54 publications

Biomarkers to identify and isolate senescent cells

Biomarkers to identify and isolate senescent cells

Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer

Contact Info

Product

Resources

About